Agenus (AGEN) Reports 100% Major Pathologic Response in dMMR Combination Cohort

Agenus plans to begin a Phase 3 trial for colon cancer treatment, with enrollment starting soon. The trial, involving 850 patients, will compare the company's treatment with standard care. Additional funding of up to $255 million is contingent on trial milestones, with enrollment expected to complete by late 2028 and results by 2030.

Agenus reported Q3 2026 revenue of $31.5M, operating income of $11.4M, and net income of $2.8M. The company had $86.9M in cash and equivalents. Agenus is preparing its Phase 3 ROBBIN trial and received first marketing authorizations for BOT+BAL in Armenia.

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.

Agenus reported Q3 2026 revenue of $31.5M, up from $30.2M in Q3 2025, with operating income of $11.4M versus a $4.6M loss. Armenia granted first marketing authorizations for BOT and BAL post-quarter. The company anticipates Q1 2027 dosing for ROBBIN and Q4 2027 interim response assessment.

Agenus Inc. (AGEN) reported positive Phase 2 UNICORN trial results for botensilimab and balstilimab in colon cancer. In pMMR/MSS patients, 36% achieved major pathologic response, 29% complete response. All dMMR/MSI-H patients responded, with 13 complete responses. No recurrences at 12 months. Agenus plans a Phase 3 trial.